Fundraising Fox
Bethesda · Seed–Series A · 13 people tracked
Also known as EPIDAREX CAPITAL MANAGEMENT LLC
Find your way into Epidarex Capital
Sign up to see every warm intro you have to Epidarex Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Epidarex Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Epidarex is a transatlantic early-stage venture capital firm that invests in and helps build breakthrough life science companies located in emerging innovation hubs. Led by a diverse team of early-stage investors, the firm positions itself as a trusted partner to founders and co-investors, leveraging deep scientific and industry networks to create value and drive shared success across its portfolio.
Source: firm website, verified Sep 29, 2026.
Team · 13 people
from curated & public directories
Founder mafia
2 people who came through Epidarex Capital went on to found or lead other companies.
What they invest in
from 27 of 41 portfolio companiesBiotech ×24Healthtech ×15Medical Devices ×8Deep Tech ×3AI & Machine Learning ×2Digital Health ×2Longevity ×2Impact & Social Good ×1
HQs:United States×10United Kingdom×5Germany×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×32 founders×44+ founders×1
Investments · 41 tracked
founders shown can be your intro pathBy year:2026 · 12022 · 22020 · 12016 · 12015 · 12014 · 17 dated
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)in
Co-investorsOno Venture Investment, Inc.Dementia Discovery FundSV Health Investors
LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk.
BiotechHealthtechMedical DevicesLeeds, GB
Professor Helen Philippou(Scientific Founder)Dr. Richard Foster(Scientific Founder)
Macomics is a drug discovery company developing therapies that target macrophage activity for diseases with limited or ineffective treatment options.
BiotechLongevity
Co-investorsScottish EnterpriseLifelink
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function.
BiotechHealthtechMedical DevicesAtlanta, US
Dr. Murali Padala(Founder)Dr. Eric Sarin(Founder, Director)Dr. Kirthana Suresh(Founder)Sai Muralidhar Padala(Executive Officer, Director)Lori Chmura(CEO)inGowri Raman(Director)
Co-investorsBroadview VenturesVensana CapitalGRA Venture
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsOxford Science EnterprisesSound BioventuresTaiho Ventures, LLCM Ventures
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
HealthtechSaint Louis, US
Jennifer Bohnert(Executive Officer)Walter Smith(Executive Officer, Director)Joseph Monahan(Executive Officer, Director)in
BoardDaniel Janiak(Director)Charles Bolten(Director)Thomas Smart(Director)
Board seatKyparissia Sirinakis· per SEC Form D
BiotechDundee, Scotland
Timothy Jason Sparey(Executive Officer)Antoine Boulanger(Executive Officer)Francisca Peixoto(Executive Officer)Christopher Andrew Woodland(Executive Officer, Director)
Board seatMary Canning· per SEC Form D · $290.5K raise · filed Sep 2026
Co-investorsO2h Ventures
Slate Bio develops regulatory T cell (Treg) therapies for treating autoimmune diseases.
BiotechDigital HealthMedical DevicesCharlottesville, US
Robert Creeden(Director)Kurt Woerpel(Executive Officer)Andrew J Krouse(Executive Officer, Director)
Board seatKyparissia Sirinakis· per SEC Form D
Co-investorsVTC Ventures
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
BiotechCrestwood, US
Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in
BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)
Co-investorsAvoro Capital AdvisorsEMBL VenturesF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta Ventures+1 more
Clyde Biosciences is a contract research organization offering predictive cardiac safety and efficacy testing using human iPSC-derived cardiomyocyte models, aimed at pharmaceutical and biotech teams assessing cardiotoxicity for clinical translation.
BiotechDeep TechHealthtech
Godfrey Smith(Chief Scientific Officer and Co-Founder)Francis Burton(Head of Software and Modeling & Co-Founder)Richard Henderson(Chief Executive Officer)Mark Bryant(Chief Business Officer)
Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.
AI & Machine LearningBiotech
Co-investorsPfizer Venture InvestmentsColumbus Venture Partners
Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD.
BiotechDeep TechCambridge, GB
Pearl Huang(President & CEO)inStephen Huhn(CMO)
Co-investorsBGVAlpha Wave Global
University of Edinburgh spin-out clinical-phase biotech developing C-Met molecular targeting technology for cancer radiotherapy and imaging.
Co-investorsScottish Investment Bank
Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.
BiotechHealthtechBrighton, GB
John Ford(Co-founder)inMartin Gosling(Founder)in
Co-investorsNovartis Venture FundVersant VenturesForbionIP GroupPanakes Partners
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investors3B Future Health FundAlbionVCBioGeneration VenturesGlobal BioAccess FundNovartis Venture FundUCL Technology Fund
The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.
HealthtechImpact & Social Good
Co-investorsYsios CapitalBioGeneration VenturesRoche Venture FundScottish National Investment BankSofinnova Partners
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in
Co-investorsGRA VentureIllumina Ventures
Lario Therapeutics develops first-in-class precision medicines aimed at disease-modifying treatments for severe neurological disorders, including developmental and epileptic encephalopathies and Parkinson's disease.
BiotechDeep Tech
Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors.
BiotechHealthtechLondon, GB
John Maher(Founder)
Co-investorsSofinnova PartnersVulpes Investment Management
Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease.
BiotechLongevityMedical Devices
Dr. Gill(Chief Scientific Officer)
Co-investorsDolby Family VenturesAMR Action FundBoehringer Ingelheim Venture Fund
Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.
BiotechMedical Devices
Adele Rowley(Chief Scientific Officer)in
Co-investorsBioGeneration VenturesRoche Venture FundSofinnova PartnersScottish National Investment Bank
RapidPulse Medical is an investor relations page showcasing multiple healthcare-focused investment firms and incubators that back medical device and healthcare technology companies.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsBroadview VenturesFlorida Opportunity FundHatteras Venture PartnersS3 VenturesSante Ventures
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation.
BiotechHealthtech
Geoff McDonough(Executive Team / Board)inChris Guiffre(Executive Team)inAlan P. Watt(Executive Team)inJyothis George(Chief Medical Officer)inNick Clarke(Executive Team)in
Co-investors5AM VenturesF-Prime CapitalSanofi VenturesSofinnova Partners
Ryme Medical develops a catheter-based therapy to treat chronic obstructive pulmonary disease (COPD) by reducing airway inflammation and improving patient outcomes.
BiotechHealthtechMedical DevicesMountain View, US
Co-investorsSeroba Life Sciences
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)inChristian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)in
Co-investorsEMBL VenturesGimvBoehringer Ingelheim Venture FundBioMedPartners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Harpoon Medical, Inc.AdorxAdoRx TherapeuticsCaldan TherapeuticsClyde BiosciencesEdinimageHarnessKodikaz Therapeutic SolutionsKynos TherapeuticsKynostxLario TherapeuticsMolecular ImagingNodTheraSIRAKOSSSyntheon 2.0
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
5 acquisitionsCONFLUENCE LIFE SCIENCES, INC.acq. by Aclaris TherapeuticsHarpoon Medical, Inc.acq. by Edwards LifesciencesApellis Pharmaceuticalsacq. by BiogenKynos Therapeuticsacq. by Dr. Falk Pharma GmbHSIRAKOSSacq. by OssDsign
Portfolio news
latest coverage across their companiesMironid · eu-startups.com · Aug 7, 2026
Frequently asked questions
- How many investments has Epidarex Capital made?
- Epidarex Capital has 41 tracked investments, 5 of which have exited, including 1 dated in the last 24 months.
- What stage does Epidarex Capital invest at?
- Epidarex Capital invests at the Seed, Series A stages.
- What is Epidarex Capital's typical check size?
- Epidarex Capital typically writes checks of $2.5M – $6.3M.
- What sectors does Epidarex Capital focus on?
- Epidarex Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Epidarex Capital located?
- Epidarex Capital is headquartered in Bethesda, US.
- Does Epidarex Capital lead rounds?
- Yes, Epidarex Capital leads investment rounds.
- Who does Epidarex Capital co-invest with?
- Epidarex Capital most often shares deals with BioGeneration Ventures, Broadview Ventures, F-Prime Capital, among 37 tracked co-investors.
Media · Podcasts & interviews
featuring the teamDr Peter Finan, BIA Board Member, Partner, Epidarex Capital on SVB collapse
BioIndustry Association - BIA · Peter Finan
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.